Alzheimer’s Disease Neuroimaging Initiative 2


This program completed in August 2016.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a landmark partnership and study supported by the FNIH that involves identifying and validating biomarkers to detect the progression of Alzheimer’s Disease (AD). ADNI 2 built upon the successes of earlier ADNI phases (ADNI and ADNI-GO) and extended the ADNI study for an additional six years (2010-2016). This longitudinal study tracked subjects with early mild cognitive impairment (MCI), late MCI, AD, and normal cognition to produce a public resource catalog of imaging, biochemical, and genetic biomarkers. The study also tested whether serial MRI and PET imaging scans; genetic testing; other biological markers (e.g. in blood, urine, and cerebrospinal fluid); and clinical and neuropsychological assessments could be used to identify the earliest changes in brain structure and function as people transition from normal cognitive aging to MCI to AD.

The third phase of ADNI (ADNI3) launched in September 2016. Learn more here.


  • To test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers (in blood, urine, and cerebral spinal fluid (CSF)), and clinical, and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD).

Results & Accomplishments

  • Developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures.
  • Contributed to a better understanding of the pathophysiology of disease and provided data which improved clinical trial efficiency.
  • Generated standardized methods and protocols for use across multiple centers defining best practices and allowing for direct comparison of results world-wide.
  • ADNI has acted as an open-access sample and data-sharing model promoting further Research, improving drug development, and ultimately benefiting public health.
  • Generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression.
  • Expanded upon the already extensive ADNI sample biorepository allowing for a more comprehensive study of AD progression.


Private-Sector Partners:

  • AbbVie*
  • Alzheimer’s Association*
  • Alzheimer’s Drug Discovery Foundation*
  • Araclon Biotech*
  • BioClinica*
  • Biogen*
  • Bristol-Myers Squibb*
  • Cerespir*
  • Cogstate*
  • Eisai*
  • Elan*
  • Euroimmun*
  • Fujirebio*
  • GE*
  • Genentech, a member of the Roche Group*
  • Ixico*
  • Janssen Research & Development, LLC*
  • Eli Lilly and Company*
  • Lumosity*
  • Lundbeck*
  • Merck Sharpe & Dohme Corp.*
  • Meso Scale Disovery*
  • NeuroRx*
  • Neurotrack*
  • Novartis*
  • Pfizer, Inc.*
  • Piramal Imaging*
  • Roche*
  • Servier*
  • Takeda*

*Provided financial or in-kind support for this program.

FNIH Contact

Leave a comment

Your email address will not be published. Required fields are marked *